Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· November 8, 2025

Fear Is Coming Back to the Junk Bond Market

View original at finance.yahoo.com
Fear Is Coming Back to the Junk Bond Market (Bloomberg) -- Junk bond investors are getting more skittish about risk. An index of CCC rated bonds in the US has dropped nearly 0.8% over the month ended Thursday, underperforming the broader high-yield market as investors increasingly avoid the riskiest debt…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Investment-grade spreads still close to historical tightness at 81 basis points while high-yield spreads aren't is a trend to watch

    80% confidence
  • Previous breakouts in distressed supply from troughs have signaled the start of a notable bout of risk aversion

    80% confidence
  • There's not much room to sweeten the terms of $1.9 billion debt swap proposal

    80% confidence
  • $600 million bankruptcy financing was needed to prevent immediate shutdown

    80% confidence
  • Credit spreads were a little unnaturally low in July

    80% confidence
  • While the share of distressed debt is small on a historic perspective, it's quite large compared to prior periods when you've had very tight spreads

    80% confidence
  • There is a greater level of caution at the first whiff of potential problems right now

    80% confidence
  • More consumer-related sectors within high-yield are weakening, like subprime lenders and retailers that cater to lower-end consumers

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com